Loading
A phase 2 trial of Durvalumab and Olaparib in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) is a phase 2 interventional study registered as NCT03459846 by AstraZeneca, with 154 participants enrolled, started 2018-03-16 and due to reach its primary completion in 2020-10-15. Interventions recorded: Durvalumab, Olaparib and Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
154 enrolled.
95% CI 3.6 to 5.6; Figures from the ClinicalTrials.gov results section (first posted 2022-10-26), not from a publication · 95% CI 1.9 to 5.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | Durva + Olaparib | 78 | 4.2 months | 0.94 (0.641 to 1.387) | 0.789 | link |
| Durva + Placebo | 76 | 3.5 months |
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.